Pangenomic Health Inc.
NARA
CNSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -1.22% | -69.30% | |||
| Gross Profit | 1.22% | 69.30% | |||
| SG&A Expenses | -53.65% | 491.42% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -52.17% | 289.92% | |||
| Operating Income | 52.17% | -289.92% | |||
| Income Before Tax | 51.17% | -346.08% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 51.17% | -346.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 51.17% | -346.08% | |||
| EBIT | 52.17% | -289.92% | |||
| EBITDA | 52.17% | -290.02% | |||
| EPS Basic | 70.56% | -299.03% | |||
| Normalized Basic EPS | 70.57% | -297.67% | |||
| EPS Diluted | 68.13% | -299.03% | |||
| Normalized Diluted EPS | 70.57% | -297.67% | |||
| Average Basic Shares Outstanding | 65.74% | 11.79% | |||
| Average Diluted Shares Outstanding | 65.74% | 11.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||